Concepedia

Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis

Ana Luisa Perdigoto, Paula Preston‐Hurlburt, Pamela Clark, S. Alice Long, Peter S. Linsley, Kristina M. Harris, Steven Gitelman, Carla J. Greenbaum, Peter A. Gottlieb, William Hagopian,

Diabetologia · 2018 · 125 citations · 15 references

DOIFull text

Open access

Concepts

References

15

Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

Kevan C. Herold, William Hagopian, Julie Auger et al. · New England Journal of Medicine · 2002 · 1.2K citations · Full text

, , +14

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

Mark D. Pescovitz, Carla J. Greenbaum, Heidi Krause‐Steinrauf et al. · New England Journal of Medicine · 2009 · 1.1K citations · Full text

, , +16

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

Nicole Sherry, William Hagopian, Johnny Ludvigsson et al. · The Lancet · 2011 · 489 citations

, , +11

C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function

Jerry P. Palmer, G. Alexander Fleming, Carla J. Greenbaum et al. · Diabetes · 2004 · 484 citations · Full text

, , +17

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial

Kevan C. Herold, Stephen E. Gitelman, Mario R. Ehlers et al. · Diabetes · 2013 · 405 citations · Full text

, , +13